Exchange Traded Concepts’s Janux Therapeutics JANX Stock Holding History

Exchange Traded Concepts’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,043	Closed	-$109K	–	1463
2025 Q1	$109K	Buy	4,043 +686	+20%	+$25.9K	﹤0.01%	1127
2024 Q4	$180K	Hold	3,357	–	–	﹤0.01%	1014
2024 Q3	$153K	Sell	3,357 -2,397	-42%	-$104K	﹤0.01%	1061
2024 Q2	$241K	Sell	5,754 -1,790	-24%	-$84K	0.01%	850
2024 Q1	$284K	Sell	7,544 -6,660	-47%	-$145K	0.01%	825
2023 Q4	$152K	Buy	14,204 +3,602	+34%	+$31.1K	﹤0.01%	831
2023 Q3	$107K	Buy	10,602 +592	+6%	+$6.83K	﹤0.01%	873
2023 Q2	$119K	Buy	+10,010	New	+$134K	﹤0.01%	913

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Exchange Traded Concepts's JANX Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 4,043 shares — an estimated $109K sold.

Exchange Traded Concepts first reported a position in JANX in Q2 2023 and held it in 8 quarters. The position peaked at $284K in Q1 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

Exchange Traded Concepts reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
Exchange Traded Concepts sold 4,043 Janux Therapeutics shares in Q2 2025, an estimated $109K.
Exchange Traded Concepts first reported a position in Janux Therapeutics in Q2 2023 and held it in 8 quarters.
Exchange Traded Concepts's Janux Therapeutics position peaked at $284K in Q1 2024.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.